But the recommendations — even those approved unanimously — mask significant dissent and disquiet among those advisers about the need for booster shots in the United States.
In interviews last week, several advisers to the Centers for Disease Control and Prevention and to the Food and Drug Administration said data show that, with the exception of adults over age 65, the vast majority of Americans are already well protected against severe illness and do not need booster shots.
All the advisers acknowledged that they were obligated to make difficult choices, based on sparse research, in the middle of a public health emergency. But some said they felt compelled to vote for the shots because of the way the federal agencies framed the questions that they were asked to consider.
Other committee experts said that they wanted to avoid confusing the public further by dissenting, or that they voted according to their views of the evidence and were simply overruled.
“These are not evidence-based recommendations,” said Dr Sarah Long, a paediatric infectious disease expert at Drexel University College of Medicine in Philadelphia, and a member of the CDC’s Advisory Committee on Immunisation Practices.
Following a series of votes, the official position of the FDA and CDC now is that among those who received an mRNA vaccine, older adults, people with certain medical conditions and those whose jobs or living situations regularly expose them to the virus can opt for a booster dose of any of the three vaccines.
“I don’t think that we have evidence that everybody in those groups needs a booster today,” said Dr Matthew Daley, senior investigator at Kaiser Permanente Colorado and a member of the CDC advisory committee.
Long and Daley both voted in favour of booster shots at their committee’s meeting Thursday, but with reservations over how the decision would be viewed by anxious Americans who might conclude mistakenly that the vaccines are ineffective.
When the CDC committee reviewed evidence for the Pfizer-BioNTech booster in September, the advisers agreed unanimously only on extra shots for adults over age 65. Two of the 15 panelists voted against booster doses for adults over age 50 with certain medical conditions.
Approval of boosters for people ages 18 to 49 with other medical risk factors squeaked by in a vote of 9-6. And the booster recommendation for people whose occupations put them at risk did not pass.
That last category was included in the final CDC recommendations only because Dr Rochelle Walensky, the agency’s director, overruled her advisers.
“You can see the hesitancy in all this,” said Dr Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia and a member of the FDA’s vaccine advisory committee. “It’s because in our hearts, I think people don’t quite agree with this notion of a booster dose.”
“The door just got bigger and bigger and bigger, it got wider and wider with each step,” Offit added. “The companies got what they wanted, the administration got what they wanted.”
In interviews, the experts bemoaned the limited data on the safety and efficacy of the booster shots. The data supporting extra doses of the Moderna and Johnson & Johnson vaccines was “of very low quality,” Dr. Kathleen Dooling, a CDC scientist, acknowledged at the committee meeting Thursday.
Still, some said they felt they had to vote in favor of booster shots of the Moderna and Johnson & Johnson vaccines because they had already recommended boosters of the Pfizer-BioNTech vaccine and did not want to deny other Americans.
“The problem that troubled me is that we don’t know if boosters are necessary,” said Dr Cody Meissner, a professor of pediatrics at Tufts University School of Medicine and a member of the FDA advisory committee.
But “if you’re going do it for one group, I think fairness kind of dictates you have to do it for all the groups,” he added.
In interviews, panelists were hesitant to voice their discomfort, saying they did not want to undercut the final decisions from the committees.
“It’s hard to show some of the misgivings, because we don’t want to have mixed messaging,” said Dr Camille Kotton, an infectious disease physician at Massachusetts General Hospital and a member of the CDC committee.
But several panelists who did not wish to speak on the record said privately that the final recommendations for booster shots were inevitable as soon as President Joe Biden promised them to all adults.
“We are in a very difficult position to do much of anything other than what everybody has already announced that we’ve done,” said Long, one of the few to publicly express her unhappiness.
Some administration officials “pay lip service to science and the evidence,” she said.
(BEGIN OPTIONAL TRIM.)
Experts outside these committees also said that Biden’s promise of boosters, in August, made it difficult for the agencies to weigh the data objectively in September and October.
“The perception is that the horse is out of the barn, and there’s not really much you can do at this point,” said Dr. Celine Gounder, an infectious disease specialist at Bellevue Hospital Center who has previously advised the Biden administration.
“The fact is, you can’t have this confusing mess — it’s going to create more problems,” she added, referring to mixed signals from the White House and federal scientists.
Much of the dissent in recent hearings sprang from one central contention: that the coronavirus vaccines, like nearly all other vaccines, should be used to prevent illness severe enough to require medical attention, not milder infection.
The bulk of the evidence presented to the federal advisers demonstrated only that the original immunizations were waning in potency against infections. The vaccines seem to be holding steady against severe COVID-19 and death, except perhaps in older Americans.
“I don’t think we ever see 100% protection from any vaccine,” Kotton said. “The goal of getting to zero is an evanescent one and, unfortunately, not really achievable.”
“People are using it because they’re so anxious about COVID, and anxious about the state of affairs in the world,” she added, referring to booster shots.
President Joe Biden receives a COVID-19 booster shot in the South Court Auditorium of the Eisenhower Executive Office Building on the White House grounds in Washington on Monday, Sept. 27, 2021. The New York Times
In December, when FDA advisers evaluated the Pfizer-BioNTech vaccine for people ages 16 and older, the evidence for its use in 16- and 17-year-olds was limited.
Dr Archana Chatterjee and three other committee members voted against the vaccine and were criticised for it. But Chatterjee said she would have voted differently if the FDA had asked about authorising the vaccine in adults 18 and older.
“We were basically told, ‘Here’s the question, and say yes or no,’” said Chatterjee, a pediatric infectious disease expert and dean of the Chicago Medical School. “We were also not given the opportunity to explain the vote.”
In subsequent meetings, the FDA allowed the science advisers to request changes to the question and to explain their votes. But they are still restricted to voting only on the data included in a company’s application.
At a recent meeting, for example, some FDA advisers said they wanted to recommend that Johnson & Johnson recipients have the option to choose any vaccine for their booster. But the FDA only asked the panel to vote on a booster of the Johnson & Johnson vaccine.
One of the panelists, Dr Stanley Perlman, said he voted yes because it was clear that Johnson & Johnson recipients would benefit from a second shot. But the unanimous vote signaled far more confidence in the Johnson & Johnson vaccine as a booster than he felt, said Perlman, an immunologist and coronavirus expert at the University of Iowa.
Perlman said he was opposed to boosters for younger people at first, but voted in favor for other reasons. In the case of health care workers, for example, “I didn’t want to have any nurses or doctors staying home because they had asymptomatic” infections, he said.
Several experts said they have tried to be clear about the limitations of the data and the rationale behind their decisions. But communicating in the midst of a pandemic has proved to be tricky.
“Through no intentional fault of anyone, the messaging has been challenging — and then there’s a lot of misinformation, which is tragic,” Kotton said.
In approving the boosters, however reluctantly, federal agencies and their advisers may have given Americans the impression that two doses were not protective enough, some experts said.
“They continue inadvertently to damn the vaccine, when what they should say is, ‘It is remarkable,’” Offit said. “It’s a miracle vaccine.”
© 2021 The New York Times Company